- Perioperative Erleada reduced risk of recurrence or death by 62% vs surgery alone in high-risk prostate cancer.
- Data supports potential label expansion for established oncology franchise.
- Positive clinical catalyst for J&J pharmaceutical division.
?? Positive AI Sentiment (+4.5 / 10)